HIV-associated Myelopathy Clinical Trial
Official title:
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
The purpose of this study is to determine whether or not intravenous immunoglobulin (lVlg),
brand name Privigen, is effective in treating a disorder called HIV-associated myelopathy
(HIVM). This drug is currently not approved by the Food and Drug Administration (FDA) for
treating this disorder.
HIVM is a spinal cord disease that occurs at any stage of HIV infection. It is not known what
causes this condition, but symptoms can include weakness in the lower body and problems with
frequent urination or problems with bowel function, trouble walking or performing sexually.
;